TW202428247A - 表面修飾的脂質奈米顆粒 - Google Patents

表面修飾的脂質奈米顆粒 Download PDF

Info

Publication number
TW202428247A
TW202428247A TW112142861A TW112142861A TW202428247A TW 202428247 A TW202428247 A TW 202428247A TW 112142861 A TW112142861 A TW 112142861A TW 112142861 A TW112142861 A TW 112142861A TW 202428247 A TW202428247 A TW 202428247A
Authority
TW
Taiwan
Prior art keywords
conjugate
lnp
sequence
antibody
scfv
Prior art date
Application number
TW112142861A
Other languages
English (en)
Chinese (zh)
Inventor
展 王
張銳
古漢
Original Assignee
美商泰斯拉治療股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商泰斯拉治療股份有限公司 filed Critical 美商泰斯拉治療股份有限公司
Publication of TW202428247A publication Critical patent/TW202428247A/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Nanotechnology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
TW112142861A 2022-11-07 2023-11-07 表面修飾的脂質奈米顆粒 TW202428247A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202263423274P 2022-11-07 2022-11-07
US63/423,274 2022-11-07
US202363478969P 2023-01-08 2023-01-08
US63/478,969 2023-01-08

Publications (1)

Publication Number Publication Date
TW202428247A true TW202428247A (zh) 2024-07-16

Family

ID=91033558

Family Applications (1)

Application Number Title Priority Date Filing Date
TW112142861A TW202428247A (zh) 2022-11-07 2023-11-07 表面修飾的脂質奈米顆粒

Country Status (3)

Country Link
EP (1) EP4615982A2 (fr)
TW (1) TW202428247A (fr)
WO (1) WO2024102772A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2024279278A1 (en) 2023-05-31 2025-12-18 Capstan Therapeutics, Inc. Lipid nanoparticle formulations and compositions

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9751945B2 (en) * 2012-04-13 2017-09-05 Whitehead Institute For Biomedical Research Sortase-modified VHH domains and uses thereof
WO2019040516A1 (fr) * 2017-08-22 2019-02-28 Rubius Therapeutics, Inc. Procédés et compositions de nanoparticules lipidiques destinés à la production de cellules érythroïdes modifiées

Also Published As

Publication number Publication date
WO2024102772A3 (fr) 2024-07-18
EP4615982A2 (fr) 2025-09-17
WO2024102772A2 (fr) 2024-05-16

Similar Documents

Publication Publication Date Title
TW202425953A (zh) 脂質奈米顆粒 (lnp) 綴合物的製備
Wang et al. Current applications and future perspective of CRISPR/Cas9 gene editing in cancer
JP7379447B2 (ja) ゲノム編集分子の細胞内送達のためのペプチドおよびナノ粒子
CA3077086A1 (fr) Systemes, procedes et compositions d'edition ciblee d'acides nucleiques
EP3230451A1 (fr) Arn guides protégés (pgrnas)
US20250257342A1 (en) Peptides and nanoparticles for intracellular delivery of genome-editing molecules
TW202425952A (zh) 脂質奈米顆粒藥物綴合物
WO2024131940A1 (fr) Fusion et son utilisation
CN116096886A (zh) 用于调节叉头框p3(foxp3)基因表达的组合物和方法
WO2025059596A1 (fr) Nanoparticules lipidiques pour l'administration de charges utiles thérapeutiques à des cellules
TW202428247A (zh) 表面修飾的脂質奈米顆粒
WO2025059599A1 (fr) Nanoparticules lipidiques pour l'administration de charges utiles thérapeutiques à des cellules
US20220280571A1 (en) Compositions and methods for treating alpha thalassemia
JP2025526403A (ja) ゲノム編集のための組成物及び方法
WO2025189161A1 (fr) Conjugaison spécifique à un site de fractions de ciblage à des nanoparticules lipidiques
WO2025193861A2 (fr) Nanoparticules lipidiques pour l'administration de charges utiles thérapeutiques à des cellules
AU2024341463A1 (en) Lipid nanoparticles for delivery of therapeutic payloads to cells
WO2025255544A2 (fr) Compositions et procédés de rétrotransposon ltr iap
WO2025019807A2 (fr) Compositions et procédés aux fins de la régulation épigénétique de l'expression de rfxap
HK40064529A (en) Peptides and nanoparticles for intracellular delivery of genome-editing molecules
JP2025535776A (ja) 遺伝子を標的化、編集又は修飾するための組成物及び方法
WO2026060316A1 (fr) Nanoparticules lipidiques pour l'administration de charges utiles thérapeutiques à des cellules
HK40006957B (en) Peptides and nanoparticles for intracellular delivery of genome-editing molecules